J Cancer Prev 2021; 26(3): 183-194
Published online September 30, 2021
© Korean Society of Cancer Prevention
1College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul, 2Department of Food and Nutrition, Kyungnam University, Changwon, Korea
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Dioscin (DS), a steroidal saponin, has been shown to have anti-cancer activity by exerting antioxidant effects and inducing apoptosis. However, the anti-cancer activity of DS in breast cancer-derived stem cells is still controversial. The purpose of this study was to evaluate the effects of DS on migration, invasion, and colony formation in MDA-MB-231 and MCF-7 cell lines and the mechanism by which it inhibits proliferation of breast cancer stem-like cells after inducing differentiation into breast cancer stem cells. DS treatment significantly reduced cellular migration, invasion, and colony formation in MDA-MB-231 and MCF-7 cells. During the differentiation process that induced manifestation of breast cancer stem-like cells, DS significantly inhibited mammosphere formation in a dose-dependent manner and increased the expression of p53 and p21 in breast cancer stem-like cells, reducing the expression of cdc2 and cyclin B1 in MDA-MB-231 cells and cyclin D, cyclin E, CDK4, and CDK2 in MCF-7 cells. Interestingly, DS treatment induced G2/M and G0/G1 cell cycle arrest in the MDA-MB-231 and MCF-7 cells, respectively. DS also increased the phosphorylation of p38 and decreased the expression levels of p-AKT and p-mTOR. These results suggest that DS regulates the p38 mitogen-activated protein kinase and AKT/mTOR signaling pathways to reduce the proliferation of breast cancer stem-like cells through cell cycle arrest. Therefore, these findings suggest that DS may serve as a potential treatment candidate targeting breast cancer stem cells.
Keywords: Dioscin, Breast cancer, AKT/mTOR
Breast cancer is one of the deadliest malignant adenocarcinomas in women, and breast cancer-related mortality is mostly caused by invasion and metastasis [1,2]. Triple-negative breast cancer (TNBC), lacking estrogen receptor α, progesterone receptors, and HER2, has a high risk of recurrence and metastasis and a low survival rate after onset . A recent study reported that TNBC cells had characteristics including metastasis, chemoresistance, and recurrence similar to breast cancer stem cells (BCSCs), which are breast-cancer initiating cells. Their therapeutic efficacy was reported in a pre-clinical study of TNBC targeting cancer stem cells (CSCs) . CSCs have stem cell properties such as self-renewal and multi-lineage differentiation and can promote the mass formation of tumors including breast cancer . CSCs, which are a subpopulation of tumor cells, are same cells as cancer stem-like cells . In various types of breast cancer, BCSCs express specific markers such as CD44+/CD24−, epithelial-specific antigen, and CD326 (EpCAM), and have aldehyde dehydrogenase activity . In particular, CD44 is a receptor for extracellular matrix hyaluronan, which acts together with the tyrosine kinase receptor as a surface marker of BCSCs and activates the signaling pathway related to the proliferation and colony formation of BCSCs. In contrast, the CD24 marker was identified as a glycoprotein on the surface of differentiated breast cancer cells .
Dandawate et al.  reported that various phytochemicals and their analogs could target CSCs by inhibiting signaling pathways responsible for self-renewal and differentiation of CSCs. The phosphatidylinositol-3-kinase (PI3K)/AKT and the mTOR signaling pathways play important roles in cancer cell growth, proliferation, motility, survival, and angiogenesis [10-12]. In chemotherapy, CSCs show multidrug resistance, leading to cancer recurrence and metastasis . As the PI3K/AKT signaling pathway can promote CSC activity , regulation of this pathway may provide a potential strategy for overcoming resistance to breast cancer therapy .
Many phytochemicals have been reported to show pharmacological efficacy and inhibit the pathogenesis of various diseases . In particular, saponin, which is a triterpenoid or steroidal glycoside widely distributed in plants, marine organisms, and some bacteria, has a wide range of biological properties . For instance, dioscin (DS), a steroidal glucoside saponin (Fig. 1A), has been used in traditional medicine for treating hypercholesterolemia, hyperglycemia, and diabetes [18-21]. DS has also been reported to inhibit cancer cell proliferation in a number of human cancer cells . The anticancer activity of DS has been demonstrated in studies on the regulation of different cell signaling processes involved in the growth, differentiation, apoptosis, and progression of cancer cells . However, studies on anticancer activity of DS in BCSCs are still lacking. Furthermore, there are no reports on the anti-migrative ability of DSs in BCSCs, although DS was shown to inhibit migration and invasion via suppressing TGF-b1-induced epithelial-mesenchymal transition in lung cancer cell lines (A549) . The purpose of this study was to compare the effects of DS on migration, invasion, and colony formation in MDA-MB-231 and MCF-7 cells that are derived from TNBC and estrogen receptor positive luminal breast cancer, respectively. Further, its anticancer activity in breast cancer stem-like cells and underlying mechanisms were also explored.
DS was purchased from Sigma-Aldrich (St. Louis, MO, USA). The compound was dissolved in 100% dimethyl sulfoxide (DMSO). A 50 mmol/L stock solution of DS was prepared and stored as small aliquots at –20°C until used. We purchased MTT, DMSO, gelatin, and horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit antibodies from Sigma-Aldrich. Fluorescein isothiocyanate (FITC)-conjugated CD44 and phycoerythrin (PE)-conjugated CD24 antibodies were purchased from BD Biosciences (San Jose, CA, USA). The phospho-specific antibodies anti-p38, anti-AKT, anti-mTOR, and specific antibodies anti-p38, anti-AKT, anti-mTOR, and AKT inhibitor LY294002 were purchased from Cell Signaling Technology (Danvers, MA, USA). HRP-conjugated β-actin, OCT4, proliferation cell nuclear antigen (PCNA), p53, p21, cdc2, cyclin B1, CDK4, cyclin D, CDK2, and cyclin E antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Human breast cancer cells (MDA-MB-231 and MCF-7) were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). The cells were cultured in 5% CO2 in a 37°C humidified atmosphere in Dulbecco’s modified Eagle’s media (DMEM) supplemented with 10% FBS and 1% antibiotics-antimycotics and maintained at 37°C and 5% CO2. The cells were passaged every 3 to 4 days.
DS cytotoxicity was assessed using the MTT assay. Cells were seeded in 96-well plates. After culturing overnight, the primary culture medium was removed, and fresh medium containing six different concentrations of DS (0, 0.01, 0.1, 1, 10, and 100 µM) was added for 24 to 72 hours. Then, 20 μL of 5 mg/mL MTT in PBS was added to each well and incubated for 4 hours. Next, the media was removed and 100 μL of DMSO was added to each well to stop the reaction. Cell viability was detected by measuring the optical density at 570 nm with a Synergy HTX plate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) and the Gen5 program.
A total of 4 × 105 cells were seeded into six-well plates and cultured for 24 hours, then an artificial wound was made with a P20 pipette tip in each well. The cells were washed three times with culture medium and fresh medium supplemented with DS (0 to 10 µM) was added. Images were captured at different time points (24 to 48 hours) under an inverted microscope equipped with a camera. The wound gap distance was quantitatively determined with ImageJ software (National Institutes of Health, Bethesda, MD, USA) and closure was determined as follows: Closure (%) = migrated cell surface area/total surface area × 100.
The cell invasion assay was performed using six-well dishes containing Transwell inserts with 8-µm polycarbonate membranes (Corning Life Sciences, Tewksbury, MA, USA). Cells (3 × 105 cells/mL) in 1.5 mL of serum-free DMEM/F12 medium were plated in the upper chamber (BD BioCoatTM MatrigelTM Invasion Chamber, Corning), while DMEM medium with 10% FBS was added to the lower chamber. In both the control and treatment groups, after 48 hours at 37°C and 5% CO2, the non-invading cells were removed from the upper chamber with a cotton swab. The invading cells were fixed in 4% paraformaldehyde for 30 minutes and stained with 0.5% crystal violet solution for 30 minutes, and the number of invasive cells in microscopic fields was counted.
Cells were seeded in triplicate at a density of 800 cells/well in six-well flat-bottom plates with 2 mL of DMEM containing 10% FBS. The cells were incubated with or without DS treatment for 48 hours and then cultured for 10 days at 37°C in a 5% CO2 incubator. The cell colonies were fixed in methanol and stained with crystal violet. Images were captured under an inverted microscope equipped with a camera. The number of colonies that contained > 50 cells was counted under a microscope. The number of colonies was quantitatively determined with ImageJ software.
For mammosphere formation, MDA-MB-231 and MCF-7 single-cell suspensions were plated at the density of 5 × 104 cells/well using the MammocultTM Human Medium Kit (Stemcell Technologies, Vancouver, BC, Canada). The cells were seeded into Ultra-Low attachment 6-well plates at 37°C and 5% CO2. After seven days in culture, the primary mammospheres were gathered by gentle centrifugation. Then, the cells were re-plated to secondary and tertiary mammospheres .
Tertiary mammospheres from the MDA-MB-231 and MCF-7 cells were trypsinized to generate single cells. The recommended concentration of human CD44-FITC and CD24-PE antibodies (BD Biosciences, San Diego, CA, USA) were added to the cell suspensions and the cells were incubated at room temperature in the dark for 30 minutes. Then, the cells were washed with PBS and analyzed using the FACSCalibur flow cytometer (BD Biosciences, San Diego, CA, USA) .
Cells were seeded in 100 mm diameter culture dishes and incubated for 24 hours, then treated with DS (0, 2.5, 5, and 10 µM) for 24 hours. The cells were collected using trypsin-EDTA and fixed with 70% cold ethanol overnight at –20°C. The fixed cells were centrifuged 4°C at 5,000 rpm for 5 minutes and washed with cold PBS, then incubated at 37°C for 30 minutes with 50 mg/mL of RNase A. The cells were stained with 50 mg/mL of propidium iodide (PI) at 37°C for 15 to 30 minutes in the dark. The DNA content of the stained cells was analyzed using CellQuest Software and a FACS Vantage SE flow cytometer (BD Biosciences, San Diego, CA, USA).
The cells were treated with DS (0, 2.5, 5, and 10 µM) for 24 hours and lysed in PRO-PREP protein extraction solution containing phosphatase and protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) for 30 minutes at 4°C. Then, they were centrifuged at 4°C at 13,000 rpm for 30 minutes. The whole protein samples (30 mg) were separated on 8% to 10% SDS PAGE and transferred onto polyvinylidene fluoride membranes polyvinylidene fluoride membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were blocked with 5% BSA (AMRESCO, Cleveland, OH, USA) and in TBS with 0.1% Tween 20 (TBS-T) for one hour at room temperature, and then with primary antibodies diluted (1:200 to 1:1,000) in 5% BSA in TBS-T overnight at 4°C. Next, the membranes were washed four times (3 minutes each) with TBS-T. After washing, the membranes were incubated with anti-rabbit/anti-mouse secondary antibody (1:1,000) for one hour at room temperature and the reactions were detected using an Advanced Electrochemiluminescence Western Blot Detection Kit (Amersham, Uppsala, Sweden). The intensities of the protein bands were measured by ImageJ software.
The data are presented as the mean ± SD for the indicated number of independently performed experiments. Statistical analysis was performed by Student’s
The inhibitory effects of DS on cell proliferation were assessed by treating MDA-MB-231 and MCF-7 cells with 0 to 100 µM of DS for 24 to 72 hours. The IC50 values of DS in MDA-MB-231 cells after 24- and 72-hour exposures was 33.55 µM and 3.23 µM, respectively, and the IC50 of DS in MCF-7 cells after 24- and 72-hour exposures was 11.03 µM and 2.50 µM, respectively (Fig. 1B and 1C). The results of this study showed that MDA-MB-231 and MCF-7 cells showed significant sensitivity to the DS treatment concentrations over time. Therefore, further analyses of the biological activities of DS were conducted following treatment at 10 µM or less in breast cancer cells.
For cellular migration analysis, scratches were made to create a gap in the cell monolayer, and a wound-healing assay was performed in different DS treatment conditions. Migration was observed for 24 hours (Fig. 2A and 2B). The change in the area after 24 hours of exposure was compared to the initial wound area in different DS treatment conditions and quantified (Fig. 2C and 2D). The relative gap area was 30.92% and 101.18% for MDA-MB-231 cells treated with 0 µM and 10 µM DS, respectively. For MCF-7 cells, the relative gap area in cells treated with 0 µM and 10 µM DS was 45.78% and 100.13%, respectively, showing that DS treatment significantly reduced migration. In addition, migrative and invasiveness of these cells were measured 48 hours after treatment of DS in Boyden’s chamber assay (Fig. 2E and 2F). Similar to the wound-healing assay results, 5 µM and 10 µM DS treatment significantly inhibited the invasion of MDA-MB-231 cells by 91.46% and 99.24%, respectively, compared to the controls. In MCF-7 cells, cell invasion was inhibited by 94.80% and 98.93% by treatment with 5 µM and 10 µM DS, respectively (Fig. 2G and 2H). To assess the inhibitory effects of DS on colony formation, MDA-MB-231 and MCF-7 cells were treated with DS for 24 hours at varying concentrations, and then cultured for 14 days (Fig. 2I and 2J). The mean colony number and size of the MDA-MB-231 and MCF-7 cells indicated that DS significantly inhibited colony formation in a concentration-dependent manner (Fig. 2K and 2L).
The anti-cancer activity of DS in BCSCs derived from MDA-MB-231 and MCF-7 cells was assessed. After culturing in differentiation medium for three weeks, mammosphere formation was observed in both the MDA-MB-231 and MCF-7 cells (Fig. 3A and 3B). The CD24low/CD44+ phenotype, which is a differentiation characteristic of BCSCs, was analyzed using FACS. After differentiated into BCSCs, the CD24low/CD44+ population increased from 3.44% to 18.19% and from 0.47% to 50.49% in MDA-MB-231 and MCF-7 cells, respectively (Fig. 3C and 3D). OCT4, a stem cell marker, and PCNA, which is expressed during cell proliferation, were highly expressed in the cancer cells. However, the expression levels rapidly decreased on day 7 and increased again until day 21 of differentiation induction in BCSCs derived from both MDA-MB-231 and MCF-7 cells (Fig. 3E and 3F).
In order to assess whether DS was able to inhibit mammosphere formation, the cells were treated with different concentrations of DS for 48 hours, after which the DS-containing medium was removed. During the 3 weeks of differentiation to BCSCs, the medium was replaced with fresh one twice per week (Fig. 4A and 4B). In the 10 µM DS-treated group, the size of the mammospheres derived from MDA-MB-231 and MCF-7 cells was significantly decreased by 54.73% and 84.20%, respectively, compared to the control group (Fig. 4C and 4D).
After confirming the inhibitory effects of DS on the growth of MDA-MB-231 and MCF-7 cells and mammosphere formation, further experiments were performed to assess whether DS could cause cell cycle arrest. After differentiation into breast cancer stem-like cells, the cells were treated with DS for 24 hours. Then, the cells were stained with PI to quantitatively analyze the DNA content using flow cytometry. DS treatment induced G2/M and G0/G1 cell cycle arrest in breast cancer stem-like cells derived from MDA-MB-231 and MCF-7 cells, respectively (Fig. 5A and 5B). To investigate the molecular events related to cell cycle arrest induced by DS in breast cancer stem-like cells, various proteins regulating the cell cycle were analyzed (Fig. 5C and 5D). DS treatment significantly increased the expression levels of p53 and p21 in MDA-MB-231 and MCF-7-derived breast cancer stem-like cells. However, the expression of cdc2 and cyclin B1 in breast cancer stem-like cells derived from MDA-MB-231 that induced G2/M cell cycle arrest was significantly decreased. In MCF-7-derived breast cancer stem-like cells, the levels of CDK4, cyclin D, CDK2, and cyclin E that induced G0/G1 cell cycle arrest were reduced.
AKT/mTOR signaling is one of the active pathways in most cancers, and this pathway plays a variety of physiological roles, including the regulation of cell growth, cycle, and survival. After differentiation into breast cancer stem-like cells for three weeks, the cells were treated with DS for 24 hours, and p38 mitogen-activated protein kinase (MAPK) and AKT/mTOR signaling was assessed. In breast cancer stem-like cells derived from MDA-MB-231 and MCF-7 cells, DS increased p-p38 MAPK expression and decreased p-AKT and p-mTOR expression in a concentration-dependent manner (Fig. 6A and 6B). Moreover, LY-294002, an inhibitor of AKT, co-treated with DS significantly inhibited the activation of p-AKT (Fig. 6C and 6D, and quantified in Fig. 6E and 6F).
As the incidence of breast cancer is increasing worldwide, research for effective treatments of BCSCs is also increasing. Although BCSCs represent a minor population of breast cancer cells, they are very aggressive and hence account for high lethality. General chemotherapy has side effects, including drug resistance, that cause toxicity to normal cells . Therefore, there is an emerging interest in treatments using natural products.
This study was the first one to show the anti-cancer activity of DS in breast cancer stem-like cells. MCF-7 cells were more sensitive to the cytotoxic effects of DS treatment compared to MDA-MB-231 cells. In contrast, Aumsuwan et al.  reported that MDA-MB-231 cells were more sensitive to DS isolated from wild yam (
The increased expression of OCT4, which is an undifferentiated stem cell marker, in CSCs has been reported to mediate the activation of growth factors, and promote cellular proliferation and metastasis in various types of malignancies . The high proliferation activity is one of the notable characteristics of CSCs. PCNA is recognized as a useful indicator of the proliferation of tumor cells, which is closely related to the cell cycles . In this study, the differentiation of MDA-MB-231 and MCF-7 cells into breast cancer stem-like cells led to a sharp decrease in the expression of OCT4 at the beginning of differentiation, followed by elevated OCT4 expression with increased differentiation induction time. Similarly, PCNA expression was also enhanced with increased differentiation induction time.
Cellular proliferation is primarily regulated by the control of the cell cycle and consists of four distinct sequential steps (G0/G1, S, G2, and M) . In eukaryotes, the cell cycle is regulated by cyclins and CDKs. Cyclin D and CDK4 regulate the G0/G1 phase, and cyclin B1 and cdc2 proteins regulate the G2/M phase . In this study, DS caused G2/M phase and G0/G1 phase arrest in MDA-MB-231 and MCF-7 cells, respectively, in a concentration-dependent manner. Furthermore, the major regulatory factors of the cell cycle checkpoints, including cdc2, CDK4, CDK2, cyclin B1, cyclin D, and cyclin E were assessed. The p53 tumor suppressor gene plays an important role in mediating cell responses by regulating various genes involved in apoptosis, cell cycle arrest, and DNA repair . Moreover, p53 induces the transcription of various genes including the CDK inhibitor p21, which is an important negative cell cycle regulator. The cyclin-CDK complex controls the cell cycle, inducing cell cycle progression. The induction of p21 leads to inhibition of the cyclin-CDK complex and consequently induces cell cycle arrest. It was observed that the expression levels of p53 and p21 were significantly increased in MDA-MB-231 and MCF-7 cells treated with DS. The cdc2-cyclin B1 complex plays a pivotal role in regulating G2/M phase transition and mitosis . In DS-treated MDA-MB-231 cells, the cdc2 and cyclin B1 expression levels were significantly decreased, indicating that DS induced G2/M phase arrest in MDA-MB-231 cells. In contrast, the cyclin D, cyclin E, CDK4, and CDK2 expression levels were decreased in a concentration-dependent manner, leading to G0/G1 cell cycle arrest in the MCF-7 cells treated with DS.
In this study, DS inhibited the activity of AKT and mTOR by inducing p38 MAPK expression. p38 MAPK is an important stress kinase involved in the regulation of inflammation, cell growth and differentiation, the cell cycle, and cell death . The PI3K/AKT/mTOR pathway also plays an important regulatory role in proliferation, migration, angiogenesis, and cell survival. This is an important pathway that may serve as a possible treatment target for breast cancer . In this study, DS increased the expression of p-p38 MAPK and decreased the expression level of p-AKT. This led to the downregulation of p-mTOR, thereby inhibiting the AKT/mTOR signaling pathway in human breast cancer stem-like cells.
In conclusion, our results show that DS treatment inhibits the mammosphere formation of breast cancer stem-like cells and induces G2/M and G0/G1 cell cycle arrest in MDA-MB-231 and MCF-7-derived stem-like cells, respectively. Moreover, DS inhibits cell proliferation by inducing p38 MAPK and regulating the AKT/mTOR signaling pathway. These findings suggest that DS may serve as a potential therapeutic candidate for the treatment of human BCSCs.
This work was supported by the Basic Science Research program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number 2017R1D1A3B03034506).
No potential conflicts of interest were disclosed.
Ji Young Jang, Eun Young Ko, Ji Soo Jung, Kyung Nam Kang, Yeon Soo Kim, Chul Woo KimJ Cancer Prev 2021; 26(4): 258-265 https://doi.org/10.15430/JCP.2021.26.4.258
Ji-Young Park, Soma Saeidi, Eun-Hee Kim, Do-Hee Kim, Hye-Kyung Na, Joo-Seob Keum, Young-Joon SurhJ Cancer Prev 2021; 26(1): 54-63 https://doi.org/10.15430/JCP.2021.26.1.54
Cassandra Winz, Nanjoo SuhJ Cancer Prev 2021; 26(1): 18-24 https://doi.org/10.15430/JCP.2021.26.1.18